Evidence map›Paper›PMID 35839251›Full record

ArticleCancer control : journal of the Moffitt Cancer Center

The Addition of Chemoradiation to Adjuvant Chemotherapy is Associated With Improved Survival Following Upfront Surgical Resection for Pancreatic Cancer With Nodal Metastases.

Ariella M Altman, McKenzie J White, Schelomo Marmor, Dip Shukla, Katherine Chang, Emil Lou, Christopher J LaRocca, Jane Y C Hui, Todd M Tuttle, Eric H Jensen and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ariella M AltmanDepartment of Surgery, 12269University of Minnesota Medical School, Minneapolis, MN, USA.
McKenzie J WhiteDepartment of Surgery, 12269University of Minnesota Medical School, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-5328-4938
Schelomo MarmorDepartment of Surgery, 12269University of Minnesota Medical School, Minneapolis, MN, USA.
Dip ShuklaDepartment of Surgery, 12269University of Minnesota Medical School, Minneapolis, MN, USA.
Katherine ChangDivision of Hematology, Department of Medicine, University of Minnesota Medical School, Oncology and Transplantation, 12269University of Minnesota, Minneapolis, MN, USA.
Emil LouDivision of Hematology, Department of Medicine, University of Minnesota Medical School, Oncology and Transplantation, 12269University of Minnesota, Minneapolis, MN, USA.
Christopher J LaRoccaOffice of Academic Clinical Affairs, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Jane Y C HuiOffice of Academic Clinical Affairs, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0002-2628-0720
Todd M TuttleOffice of Academic Clinical Affairs, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Eric H JensenOffice of Academic Clinical Affairs, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
Jason W DenboOffice of Academic Clinical Affairs, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
University of Minnesota Medical Center · USFox Chase Cancer Center · USMoffitt Cancer Center · USUniversity of Minnesota · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is unclear whether the addition of chemoradiation (CRT) to adjuvant chemotherapy (CT) following upfront resection of pancreatic ductal adenocarcinoma (PDAC) provides any benefit. While some studies have suggested a benefit to combined modality therapy (CMT) (adjuvant CT plus CRT), it is not clear if this benefit was related to increased CT usage in patients who received CMT. We sought to clarify the use of CMT in patients who underwent upfront resection of PDAC.

methodsPatients with non-metastatic PDAC were retrospectively identified from the linked SEER-Medicare database. Those who underwent upfront resection were identified and divided into two cohorts - patients who received adjuvant CT and patients who received adjuvant CMT. Cohorts were compared. Univariate analysis described patient characteristics. Kaplan-Meier and multivariable Cox proportional hazards modeling were used to estimate overall survival (OS).

results3555 patients were identified; 856 (24%) received CT and 573 (16%) received CMT. The median number of CT doses was 11 for both groups. Patients who received CMT were younger, diagnosed in the earlier time frame, and had fewer comorbidities. The median OS was 21 months and 18 months for those treated with CMT and CT ( DISCUSSION: Receipt of CMT following upfront resection for PDAC was associated with improved survival, which was confined to node-positive patients. The role of adjuvant CMT in PDAC with nodal metastases warrants further study.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAgedChemoradiotherapy, AdjuvantChemotherapy, AdjuvantHumansMedicareRetrospective StudiesUnited Stateschemoradiationcombined modality therapylymph nodesmedicarepancreatic ductal adenocarcinomasurgerysurveillance epidemiology and end results

Identifiers

PMID35839251
PMCPMC9290159
OpenAlexW4285506731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.